30
Design of Experiments for Pharmaceutical Process Optimization 1 ASQ Fall Technical Conference October 15, 2004 Robert P. Cogdill, Arwa S. El-Hagrasy, Carl A. Anderson, James K. Drennen, III

design_exp_pharm_opt

Embed Size (px)

DESCRIPTION

Robert P. Cogdill, Arwa S. El-Hagrasy, Carl A. Anderson, James K. Drennen, III ASQ Fall Technical Conference October 15, 2004 1 www.dcpt.duq.edu 2 “(Six Sigma/TQC) will not work (in pharma) because the processes and materials are too complex…” -Anonymous Effective DOE will provide the key to greater understanding of pharmaceutical processes… …thereby enabling Total Quality Control 3

Citation preview

Page 1: design_exp_pharm_opt

Design of Experiments for Pharmaceutical Process Optimization

1

ASQ Fall Technical ConferenceOctober 15, 2004

Robert P. Cogdill, Arwa S. El-Hagrasy, Carl A. Anderson, James K. Drennen, III

Page 2: design_exp_pharm_opt

www.dcpt.duq.edu

2

Page 3: design_exp_pharm_opt

3

“(Six Sigma/TQC) will not work (in pharma) because the processes and materials are too complex…”

-Anonymous

“No wind favors him who has no destined port.”-Montaigne

Effective DOE will provide the key to greater understanding of pharmaceutical processes…

…thereby enabling Total Quality Control

Page 4: design_exp_pharm_opt

Hierarchy of Process Understanding

4

Current State:

• “Trial-n-Error”• Batch Processes

• ‘silo’ conditions• ‘black-box’ controls

• Quality-by-Inspection

Adapted from: Ajaz Hussain, AAPS 39th Pharm. Technologies Conf. at Arden House, Jan. 2004

Page 5: design_exp_pharm_opt

Hierarchy of Process Understanding

5

Desired State:

• 1st Principles Understanding• Robust Processes• Total Quality Control

Adapted from: Ajaz Hussain, AAPS 39th Pharm. Technologies Conf. at Arden House, Jan. 2004

Page 6: design_exp_pharm_opt

Hierarchy of Process Understanding

6

•DOE Optimization•Mechanistic Understanding•Process Analytical Technology (PAT)

•Feed-forward control•Real-Time-Release (RTR)•Quality-by-Design

Intermediate State:

Adapted from: Ajaz Hussain, AAPS 39th Pharm. Technologies Conf. at Arden House, Jan. 2004

Page 7: design_exp_pharm_opt

Typical Solid Dosage Process

7

FBDrier

Wet Granulation

Dispensory

Milling/Sizing

Blending

TabletPress

CoatingInspection &

Release

PAT PAT PAT PAT

PAT PAT PAT

Page 8: design_exp_pharm_opt

“Ideal” Solid Dosage Process

8

DryGranulation

Dispensory

Milling/Sizing

TabletPress

Coating

Inspection &Release

BlendingProduct Quality Expectation

• Embedded PAT

• Feed-forward control

•Transfer functions abstract unit operations

•Model-predictive control

•Continuous optimization via feedback

Page 9: design_exp_pharm_opt

The Optimization Problem

9

Experimental trials are expensive and time-consuming (e.g.- dissolution)The processes “cascade”, requires an integrated approach to optimizationExpect significant, complex interactionsGenerally, must be performed anew for each formulation

What will we learn that can be carried forward?Will process characterization endure scale up?

Page 10: design_exp_pharm_opt

Fluidized Bed Drying

10

Input factors:Input air volume, humidity, temperatureProduct moisture contentMaterial propertiesLoading

Output factors:Drying timeMaterial properties

Used for other operations such as coating and granulation

Page 11: design_exp_pharm_opt

Wet Granulation

11

Input factors:Rotational speedProcess scaleProduct moisture contentBinder fluid applicationMaterial properties

Output factors:Granulation timeParticle size distributionMaterial propertiesTablet performance

Page 12: design_exp_pharm_opt

Roller Compaction

12

Input factors:Feed rate (volume)Roll speedRoll pressureComposition (compressibility)

Output factors:Tensile strength/hardnessGranule sizeTablet performance

Page 13: design_exp_pharm_opt

Tablet Compression

13

Input factors:Compression forceDwell timeTablet size & shapeMaterial properties

Output factors:Tablet hardnessFriabilityTablet performanceUniformity

Page 14: design_exp_pharm_opt

DOE Case Study

14

A Process Analytical Technology Approach to Near-Infrared Process Control of Pharmaceutical Powder Blending

Part I: D-Optimal Design for Characterization of Powder Mixing and Preliminary Spectral Data Evaluation

Arwa S. El-Hagrasy1, Frank D’Amico2, James K. Drennen, III2

1Bristol-Myers Squibb, 2Duquesne University

-In Processwww.dcpt.duq.edu

Page 15: design_exp_pharm_opt

Powder Blending

15

Kinetic mixing of active pharmaceutical ingredients (API) with excipientsAdequacy of blending directly impacts content uniformityOptimal blend time is established during scale-up and validationBlend time is affected by variation in material physico-chemical properties, environmental conditions, process scale, speed, loading

Page 16: design_exp_pharm_opt

Powder Blending

16

Project objectives:Characterization of the powder blending process for a binary mixtureInvestigation of the sensitivity of near-infrared (NIR) spectroscopy to changes in the physicochemical properties of powders during mixing

Page 17: design_exp_pharm_opt

Powder Blending

17

Factors varied:Drug concentrationRotational speedHumidity

Factors held constantMaterial propertiesTemperatureFill levelLoading scheme

Page 18: design_exp_pharm_opt

Powder Blending

18

8-qt plastic V-blender (Patterson-Kelly)Blend composition

Salicyclic acid (SA), 30.5 µm particle sizeLactose, 115.5 µm particle size

Input factor levelsRelative humidity: 20%, 60%SA concentration: 3%, 7%, 11%Rotation speed: 12.8, 20.3 rpm

Page 19: design_exp_pharm_opt

Powder Blending

19

Sampling methodBlend process monitored for 50 minutesStopped at pre-determined time intervals for sampling with thief probe and NIR analysisThief samples analyzed via UV spectroscopy (296.9 nm)

Page 20: design_exp_pharm_opt

Powder Blending

20

0

10

20

30

40

50

60

70

80

0 5 10 15 20 25 30 35 40 45 50

Time (min)

%R

elat

ive

Stan

dard

Dev

iatio

n

Left shell

Right shell

Top

Middle

Bottom

•Typical powder blend profiles

Page 21: design_exp_pharm_opt

D-Optimal Design

21

Experimental design generated using JMPND = 16 experiments D-Efficiency Calculation:

D-Efficiency of best design: 68%

⎟⎟⎠

⎞⎜⎜⎝

⎛=− pefficiencyD

1'

D

XXN1100

Page 22: design_exp_pharm_opt

D-Optimal Design

22

Experimental ConditionsOrder

Humidity Salicylic acid Concentration

Blender Speed *

I 20% 3% 12.8

II 20% 11% 12.8

III 20% 3% 20.3

IV 20% 7% 12.8

V 20% 7% 20.3

VI 20% 11% 20.3

VII 20% 11% 12.8

VIII 60% 3% 20.3

IX 60% 11% 20.3

X 60% 7% 12.8

XI 60% 7% 20.3

XII 60% 7% 20.3

XIII 60% 11% 12.8

XIV 60% 3% 20.3

XV 60% 7% 12.8

XVI 60% 3% 12.8

* Blender speed measured in rpm

Page 23: design_exp_pharm_opt

23

Thief-Sample Position Dependency

• Outliers were flagged during UV analysis as samples exceeding 1.5x IQR

RL

1 2

3 4

5

0

5

10

15

20

25

30

35

40

1 2 3 4 5

Location

% O

utlie

rs

BA

Page 24: design_exp_pharm_opt

Results

24

Adj. R2 > 0.68 (.81, after removing outlier)

5

10

15

20

25

End

poin

t (m

in) A

ctua

l

5 10 15 20 25

End point (min) Predicted

-6

-4

-2

0

2

4

6

End

poin

t (m

in) R

esid

ual

5 10 15 20 25

End point (min) Predicted

A B

Page 25: design_exp_pharm_opt

Results

25

00.10.20.30.40.50.60.70.80.9

1

Blender Speed Humidity Concentration

P = 0.0002

P = 0.002

P = 0.0331

Page 26: design_exp_pharm_opt

Red = L.S. Effect Mean, Yellow = (10 x Stdev)

26

0

2

4

6

8

10

12

14

16

18

20% 60% 3 7 11 12.8 20.3

Humidity SA Concentration Rotational Speed

Page 27: design_exp_pharm_opt

Case Study Conclusions

27

All main effects were found to be significantHumidity is especially important since it is difficult to controlPoor repeatability of blend time was observed among replicate blends

PAT will provide a more realistic means of controlling powder mixing

NIR spectroscopy was found to be effective in determining blend uniformity (not shown)

Page 28: design_exp_pharm_opt

Blueprint for Optimization

28

Feasibility study and risk analysis provide initial starting points, and optimization constraintsDOE

Flexibility to accommodate disparate data typesInclude first-order/two-way interactionsShould be sufficient to estimate transfer functions

Subsequent experiments are used to “fine-tune” the transfer function

Page 29: design_exp_pharm_opt

Blueprint for Optimization

29

DOE will reveal most effective CCP’s for process analysisTransfer functions will allow estimation of “realistic” critical control limitsTransfer functions should include sensor data, enable model-predictive controlProcess characterization should be integrated with PAT method developmentInformation management will be critical for continuous improvement of process control

Page 30: design_exp_pharm_opt

Thank You!

30

• FOSS NIRSystems• Jim Fete, Beckman Coulter• Lamija Begic• Damir Begic• Amber Fullmer• Mohamed Ghorab• David Molseed• Katie Reardon

www.dcpt.duq.edu